Orca-Q
Phase 1Biologic
Orca-Q is one of 17 biologic programs targeting Primary Progressive Multiple Sclerosis. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Primary Progressive Multiple Sclerosis
#DrugCompanyPhaseTrials
1Gilenya
NovartisApproved
Ocrevus
RochePhase 3
Glucophage
EMD SeronoApproved
Medrol
PfizerPhase 3
Droxia
TTheravia
Phase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Plaquenil
Alnylam PharmaceuticalsPhase 2
Tecfidera
BiogenPhase 2
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Fenebrutinib
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Orca-Q. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SStanford University